JP2020505352A - インターロイキン−２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用 - Google Patents

インターロイキン−２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用 Download PDF

Info

Publication number
JP2020505352A
JP2020505352A JP2019538525A JP2019538525A JP2020505352A JP 2020505352 A JP2020505352 A JP 2020505352A JP 2019538525 A JP2019538525 A JP 2019538525A JP 2019538525 A JP2019538525 A JP 2019538525A JP 2020505352 A JP2020505352 A JP 2020505352A
Authority
JP
Japan
Prior art keywords
alpha
phe
lys
peptide
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019538525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505352A5 (enExample
Inventor
アショク バンダーリー，
アショク バンダーリー，
グレゴリー ボーン，
グレゴリー ボーン，
Original Assignee
プロタゴニスト セラピューティクス， インコーポレイテッド
プロタゴニスト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロタゴニスト セラピューティクス， インコーポレイテッド, プロタゴニスト セラピューティクス， インコーポレイテッド filed Critical プロタゴニスト セラピューティクス， インコーポレイテッド
Publication of JP2020505352A publication Critical patent/JP2020505352A/ja
Publication of JP2020505352A5 publication Critical patent/JP2020505352A5/ja
Priority to JP2022193564A priority Critical patent/JP7819087B2/ja
Priority to JP2025088409A priority patent/JP2025162551A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019538525A 2017-01-18 2018-01-18 インターロイキン−２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用 Withdrawn JP2020505352A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022193564A JP7819087B2 (ja) 2017-01-18 2022-12-02 インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
JP2025088409A JP2025162551A (ja) 2017-01-18 2025-05-28 インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447778P 2017-01-18 2017-01-18
US62/447,778 2017-01-18
PCT/US2018/014257 WO2018136646A1 (en) 2017-01-18 2018-01-18 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022193564A Division JP7819087B2 (ja) 2017-01-18 2022-12-02 インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用

Publications (2)

Publication Number Publication Date
JP2020505352A true JP2020505352A (ja) 2020-02-20
JP2020505352A5 JP2020505352A5 (enExample) 2021-02-25

Family

ID=62908287

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019538525A Withdrawn JP2020505352A (ja) 2017-01-18 2018-01-18 インターロイキン−２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
JP2022193564A Active JP7819087B2 (ja) 2017-01-18 2022-12-02 インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
JP2025088409A Pending JP2025162551A (ja) 2017-01-18 2025-05-28 インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022193564A Active JP7819087B2 (ja) 2017-01-18 2022-12-02 インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
JP2025088409A Pending JP2025162551A (ja) 2017-01-18 2025-05-28 インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用

Country Status (6)

Country Link
US (2) US20200207822A1 (enExample)
EP (1) EP3570864B1 (enExample)
JP (3) JP2020505352A (enExample)
AU (1) AU2018210174B2 (enExample)
CA (1) CA3049889A1 (enExample)
WO (1) WO2018136646A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7534382B2 (ja) * 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
WO2021007433A1 (en) * 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) * 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
TW202332683A (zh) * 2021-07-14 2023-08-16 美商健生生物科技公司 介白素－２３受體之肽抑制劑
AU2022402440A1 (en) 2021-12-01 2024-05-30 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CA3260606A1 (en) 2022-06-30 2024-01-04 Sanofi NEW PEPTIDES FOR USE AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS
CA3261954A1 (en) * 2022-07-14 2024-01-18 Janssen Pharmaceutica Nv IL-23 CYCLIC PEPTIDE INHIBITORS
IL322125A (en) * 2023-01-16 2025-09-01 Janssen Pharmaceutica Nv Formulations of interleukin-23 receptor peptide inhibitors linked to lipid residues
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2025170982A2 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011208A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166138A1 (en) * 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9605027B2 (en) * 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
MX384213B (es) 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
WO2018089693A2 (en) * 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011208A1 (en) * 2014-07-17 2016-01-21 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Also Published As

Publication number Publication date
JP2023014346A (ja) 2023-01-26
WO2018136646A1 (en) 2018-07-26
JP2025162551A (ja) 2025-10-27
EP3570864B1 (en) 2026-02-18
EP3570864C0 (en) 2026-02-18
CA3049889A1 (en) 2018-07-26
US20200207822A1 (en) 2020-07-02
EP3570864A1 (en) 2019-11-27
AU2018210174B2 (en) 2022-04-07
EP3570864A4 (en) 2020-12-30
JP7819087B2 (ja) 2026-02-24
US20240132558A1 (en) 2024-04-25
AU2018210174A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
JP7819087B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
US11845808B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US12018057B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7670605B2 (ja) インターロイキン－２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
US11041000B2 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021007433A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2021146458A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
HK40083331A (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220323

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221202

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221202

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221213

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221214

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20221220